New Data Highlights Etrasimod’s Potential for Atopic Dermatitis
Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, offers promise as a new therapeutic option for atopic dermatitis, according to a late-breaking study presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021.
Press Release
New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results
Dec 09, 2022 View All Press Releases